Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers

• DOI: 10.1016/j.jchromb.2024.124123
• Publication Date: 2024-04-09T16:23:30Z
• Authors: Dino Luethi; Deborah Rudin; Isabelle Straumann; Jan Thomann; Isidora Avedisian; Matthias E. Liechti; Urs Duthaler
• Keywords: MDMA

3,4-Methylenedioxymethamphetamine (MDMA) is an entactogen with therapeutic potential. The two enantiomers of MDMA differ regarding their pharmacokinetics and pharmacodynamics but the chiral pharmacology needs further study in clinical trials. Here, achiral enantioselective high performance liquid chromatography-tandem mass spectrometry method for quantification its psychoactive phase I metabolite 3,4-methylenedioxyamphetamine (MDA) human plasma were developed validated. analytes detected by positive electrospray ionization followed multiple reaction monitoring. calibration range was 0.5-500 ng/mL analysis both analytes, 0.5-1,000 analysis, 1-1,000 MDA analysis. Accuracy, precision, selectivity, sensitivity bioanalytical methods accordance regulatory guidelines. Furthermore, accuracy precision maintained when racemic calibrations used to measure quality control samples containing only one enantiomers. Likewise, enantiomeric could be reliably quantify samples. employed assess pharmacokinetic parameters participants treated or assessed comparable. In conclusion, useful simultaneous subjects MDMA. However, as do not undergo inversion, separation necessary